Logo 1 Logo 2

Clinical Trial Details

Trial ID: L4406
Source ID: NCT02851849
Associated Drug: Lgd-6972-5 Mg
Title: A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus
Acronym:
Status: COMPLETED
Study Results: NO
Results:
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: LGD-6972-5 mg|DRUG: LGD-6972-10 mg|DRUG: LGD-6972-15 mg|OTHER: Placebo
Outcome Measures: Primary: Change from baseline in HbA1c, 12 Weeks | Secondary: Change from baseline in HbA1C, Baseline to Weeks 2,4,8|Change from baseline in fasting glucose, Baseline to Weeks 2,4,8 and 12|Change from baseline values for fasting glucagon, Baseline to Weeks 2,4,8 and 12|Change from baseline values for fasting GLP-1 (total and active), Baseline to Weeks 2,4,8 and 12|Change from baseline values for fasting insulin, Baseline to Weeks 2,4,8 and 12|Change from baseline values for fasting lipids (total, LDL, and HDL cholesterol and triglycerides), Baseline to Weeks 2,4,8, and 12|Change from baseline in blood pressure (systolic and diastolic), Baseline to Weeks 2,4,8, and 12|Change from baseline in body weight, Baseline to Weeks 2,4,8 and 12 | Other: Exploratory Objective - Change from baseline from an Oral Glucose Tolerance Test (area under the curve for glucose, glucagon, insulin, C-peptide, and total and active GLP-1), Baseline, 12 Weeks
Sponsor/Collaborators: Sponsor: Ligand Pharmaceuticals
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE2
Enrollment: 148
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Start Date: 2016-09
Completion Date: 2017-06
Results First Posted:
Last Update Posted: 2018-01-12
Locations: Tuscumbia, Alabama, 35674, United States|Chandler, Arizona, 85224, United States|Surprise, Arizona, 85374, United States|Huntington Park, California, 90255, United States|Los Angeles, California, 90057, United States|Montclair, California, 91763, United States|North Hollywood, California, 91606, United States|San Diego, California, 92161, United States|Denver, Colorado, 80209, United States|Brooksville, Florida, 34601, United States|Miami, Florida, 33014, United States|Orlando, Florida, 32804, United States|Tampa, Florida, 33607, United States|Chicago, Illinois, 60607, United States|Las Vegas, Nevada, 89119, United States|Albuquerque, New Mexico, 87102, United States|Hopewell Junction, New York, 12533, United States|Durham, North Carolina, 27710, United States|Greensboro, North Carolina, 27410, United States|Franklin, Ohio, 45005, United States|Munroe Falls, Ohio, 44262, United States|Summerville, South Carolina, 29485, United States|Carrollton, Texas, 75007, United States|Dallas, Texas, 75230, United States|Houston, Texas, 77036, United States|Houston, Texas, 77074, United States|Houston, Texas, 77099, United States|Katy, Texas, 77450, United States|Manassas, Virginia, 20110, United States
URL: https://clinicaltrials.gov/show/NCT02851849

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress